Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.

[1]  F. Giles,et al.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism , 2012, International journal of cancer.

[2]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Sonneveld,et al.  Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. , 2011, Blood.

[4]  T. Yamauchi,et al.  A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. , 2011, Leukemia research.

[5]  H. Kantarjian,et al.  Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Schellens,et al.  Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Bush,et al.  Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. , 2010, Cancer research.

[8]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[9]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[10]  J. Fitzgibbon,et al.  AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. , 2009, Cancer research.

[11]  Stephen S. Taylor,et al.  Mitotic drivers—inhibitors of the Aurora B Kinase , 2009, Cancer and Metastasis Reviews.

[12]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[13]  R. Hills,et al.  Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors , 2022 .

[14]  K. Mills,et al.  Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts , 2008, Haematologica.

[15]  H. Brenner,et al.  Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century , 2008, Haematologica.

[16]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[17]  Taizo Tasaka,et al.  A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia , 2007, Molecular Cancer Therapeutics.

[18]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[19]  T. Lister,et al.  The Activity of the Novel Aurora Kinase B Inhibitor AZD1152 in Acute Myeloid Leukaemia Cells. , 2005 .

[20]  Erich A Nigg,et al.  Aurora kinases link chromosome segregation and cell division to cancer susceptibility. , 2004, Current opinion in genetics & development.

[21]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[23]  M. Tallman,et al.  Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? , 1997, Blood.